Kentucky's bid to fund ibogaine research with opioid settlement money stalls
A 2023 proposal to direct $42 million in opioid settlement funds toward an ibogaine clinical trial was withdrawn after leadership changes at the commission overseeing the allocation.
When the Kentucky Opioid Abatement Advisory Commission first floated the idea of funding an ibogaine clinical trial in mid-2023, addiction researchers across North America took notice. The proposal would have directed $42 million in state opioid settlement funds toward what would have been the largest single investment in ibogaine research in U.S. history.
Two years later, the proposal has been quietly shelved. The commission's new leadership has signaled a return to funding established interventions — medication-assisted treatment, naloxone distribution, recovery housing — citing both the regulatory status of ibogaine and unresolved cardiac safety concerns documented in observational studies.
Researchers who supported the proposal note that the withdrawal does not reflect new clinical data, but rather a shift in the political calculus around how settlement funds should be allocated. Several have since redirected their efforts toward state legislatures in Ohio and Texas, where parallel funding conversations remain active.
What the Kentucky episode illustrates, more than anything, is the fragility of the funding pathway for ibogaine research. Without FDA approval, federal grant mechanisms remain largely closed; without federal grant mechanisms, researchers depend on a patchwork of state funds, private philanthropy, and offshore observational data. Each of those sources can evaporate with a single change in leadership.
"The political appetite for psychedelic-adjacent treatments is uneven, and ibogaine carries the additional weight of cardiac safety questions that mainstream regulators have not yet resolved."